OncoCyte Corp (OCX)
2.90
-0.10
(-3.33%)
USD |
NASDAQ |
Nov 04, 16:00
OncoCyte Net Income (Quarterly): -4.53M for June 30, 2024
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
Date | Value |
---|---|
June 30, 2024 | -4.53M |
March 31, 2024 | -9.129M |
December 31, 2023 | -15.99M |
September 30, 2023 | -6.489M |
June 30, 2023 | -8.333M |
March 31, 2023 | 3.033M |
December 31, 2022 | -44.98M |
September 30, 2022 | -9.333M |
June 30, 2022 | -8.30M |
March 31, 2022 | -10.29M |
December 31, 2021 | -35.88M |
September 30, 2021 | -13.80M |
June 30, 2021 | -10.49M |
March 31, 2021 | -3.919M |
December 31, 2020 | -6.309M |
September 30, 2020 | -6.783M |
June 30, 2020 | -9.108M |
March 31, 2020 | -7.732M |
December 31, 2019 | -7.954M |
September 30, 2019 | -5.225M |
Date | Value |
---|---|
June 30, 2019 | -5.383M |
March 31, 2019 | -3.864M |
December 31, 2018 | -4.499M |
September 30, 2018 | -2.971M |
June 30, 2018 | -4.505M |
March 31, 2018 | -3.778M |
December 31, 2017 | -3.96M |
September 30, 2017 | -6.906M |
June 30, 2017 | -3.804M |
March 31, 2017 | -4.704M |
December 31, 2016 | -3.103M |
September 30, 2016 | -2.595M |
June 30, 2016 | -2.543M |
March 31, 2016 | -2.928M |
December 31, 2015 | -3.539M |
September 30, 2015 | -2.416M |
June 30, 2015 | -1.411M |
March 31, 2015 | -1.369M |
December 31, 2014 | -1.507M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-44.98M
Minimum
Dec 2022
3.033M
Maximum
Mar 2023
-11.39M
Average
-8.333M
Median
Jun 2023
Net Income (Quarterly) Benchmarks
Fonar Corp | 0.8304M |
XWELL Inc | -1.996M |
ProPhase Labs Inc | -6.153M |
Applied DNA Sciences Inc | 1.880M |
Veracyte Inc | 5.734M |
Net Income (Quarterly) Related Metrics
Revenue (Quarterly) | 0.104M |
Total Expenses (Quarterly) | 5.767M |
EPS Diluted (Quarterly) | -0.36 |
Enterprise Value | 39.57M |
Gross Profit Margin (Quarterly) | 48.08% |
Profit Margin (Quarterly) | -4.36K% |
Earnings Yield | -150.7% |
Normalized Earnings Yield | -89.15 |